- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2004. No further regulatory milestones for the originator product.
- Why 3/10
- Tysabri is an already-approved, marketed drug with no pending regulatory decision or binary catalyst. For Royalty Pharma, it is one of 35+ royalty assets in a diversified portfolio. The drug faces gradual biosimilar erosion, but this is a commercial headwind, not a binary event. No hard, dated catalyst exists for Tysabri in the next 12 months, so the impact score is capped at 3-5 per the rubric for approved drugs with no pending decision.
Tysabri has no upcoming binary catalysts; it is a mature product in gradual biosimilar-driven decline. For Royalty Pharma, the key question is how quickly Tysabri royalties erode versus growth in the rest of the portfolio. Watch Biogen's quarterly Tysabri sales reports for the pace of market share loss to Tyruko, and monitor Royalty Pharma's portfolio receipts disclosures for the Tysabri royalty trend. Royalty Pharma's next portfolio-wide catalyst is the PDUFA date for neladalkib on November 27, 2026, a separate drug entirely.
Price Chart
Executive Summary
Tysabri (natalizumab) is a mature, FDA-approved monoclonal antibody for relapsing forms of multiple sclerosis and Crohn's disease, developed and marketed by Biogen Inc. Royalty Pharma plc (RPRX) is not the developer but owns a royalty stream on global Tysabri sales, acquired from Perrigo in 2017 for up to $2.85 billion. The royalty rate is reportedly 18% of annual net global sales up to $2 billion and 25% above that. Tysabri generated $1.665 billion in global sales in 2025 (down 2.9% year-over-year), and faces growing biosimilar competition from Tyruko (Sandoz/Novartis), which launched in Europe in 2023 and the US in November 2025. Royalty Pharma expects Tysabri royalty receipts to decline in 2026. For Royalty Pharma investors, Tysabri is a gradually declining asset within a broadly diversified portfolio of 35+ commercial-stage royalties, where growth from other products is offsetting the Tysabri headwind.
How It Works
Tysabri is a monoclonal antibody that blocks immune cells from crossing into the brain and spinal cord. It works by binding to a protein (alpha-4 integrin) on the surface of inflammatory immune cells, preventing them from attaching to and passing through the blood-brain barrier. This reduces the immune attack on nerve cells in multiple sclerosis and inflammation in Crohn's disease.
Trial Status
Tysabri was initially FDA-approved in November 2004 for relapsing forms of multiple sclerosis. It was temporarily withdrawn from the market in 2005 due to safety concerns (PML risk) but returned in 2006 under a restricted distribution program (TOUCH). It was also approved for moderately to severely active Crohn's disease in 2008. The drug is now a mature, marketed product with over 20 years of real-world use. A biosimilar (Tyruko, by Sandoz/Novartis) was FDA-approved in August 2023 and launched in Europe in 2023 and the US in November 2025.
The Two-Sided Case
Upcoming Catalysts
- None for Tysabri itself. The drug is a mature marketed product with no pending regulatory decisions. Royalty Pharma's next portfolio catalyst is the PDUFA date for neladalkib (a different drug) on November 27, 2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Royalty Pharma plc PRESS-RELEASE RPRX ·Originating report